

Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS

Г	APPLICATION NO.	FILING DATE	FIRST NAMED INV	ENTOR	ATTO	RNEY DOCKET NO.
_	09/211,69	91 12/14/	98 GILBERT		. M	14137-129-10
٦	·				EXAMINER	
	020350 HM22/0329 TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO CA 94111			. •	TUNG.P.	
					ART UNIT	PAPER NUMBER
					1652 DATE MAILED:	5 03/29/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Office Action Summary

Application No. 09/211,691 Applicant(s)

Examiner

Gilbert et al. Group Art Unit

1652



	Peter Tung	1652	
Responsive to communication(s) filed on			<u> </u>
☐ This action is FINAL .			
☐ Since this application is in condition for allowance excel in accordance with the practice under Ex parte Quayle,		n as to the me	rits is closed
A shortened statutory period for response to this action is is longer, from the mailing date of this communication. Fai application to become abandoned. (35 U.S.C. § 133). Ext. 37 CFR 1.136(a).	lure to respond within the period	for response	will cause the
Disposition of Claims			
	is/are	pending in the	application.
Of the above, claim(s)	is/are w	ithdrawn from	consideration.
☐ Claim(s)	is	/are allowed.	
Claim(s)		s/are rejected.	
Claim(s)		s/are objected t	0.
X Claims 1-35			
Application Papers See the attached Notice of Draftsperson's Patent Draftsperson's Pate	er. ority under 35 U.S.C. § 119(a)-(ies of the priority documents have been been been been been been been be	ve been _ · Rule 17.2(a)).	·
Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Page Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PT Notice of Informal Patent Application, PTO-152	O-948		
SEE OFFICE ACTION	ON THE FOLLOWING PAGES		

Application/Control Number: 09/211,691

Art Unit: 1652

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-10, 23-27 and 33-35, drawn to DNA encoding a fusion polypeptide, vectors, transformed host cells and a method of making a fusion polypeptide, classified in class 435, subclass 193.

- II. Claims 28-30, drawn to a glycosyltransferase fusion polypeptide, classified in class435, subclass 193.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions Group I and Group II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product can be made by a different process such as peptide synthesis.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 4. This application contains claims directed to the following patentably distinct species of the claimed invention: sialyltransferases, N-acetylglucoaminyltransferases, N-

Page 2

Application/Control Number: 09/211,691

Art Unit: 1652

acetylgalactosaminyltransferases, fucosyltransferases, galactosyltransferases, glucuronosyltransferases, xylosyltransferases and mannosyltransferases.

Page 3

With the election of Group I, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-7, 23-27 and 33-35 are generic.

Upon the species election of sialyltransferases, claims 11-13 will be examined with the claims of Group I. Upon the species election of galactosyltransferases, claims 14 and 15 will be examined with the claims of Group I. Upon the species election of fucosyltransferases, claims 16 and 17 will be examined with the claims of Group I. Claim 17 contains claims directed to patentably distinct species of the claimed invention. Upon the species election of N-acetylgalactosaminyltransferases, claims 18 and 19 will be examined with the claims of Group I. Upon the species election of N-acetylglucoaminyltransferases, claims 20 and 21 will be examined with the claims of Group I. Upon the species election of mannosyltransferases, claim 22 will be examined with the claims of Group I.

Additionally, claim 10 will be examined to the extent of the corresponding nucleotide sugar substrate of the elected glycosyltransferase.

5. This application contains claims directed to the following patentably distinct species of the claimed invention: the accessory enzymes of claim 9.

Application/Control Number: 09/211,691 Page 4

Art Unit: 1652

With the election of Group I, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-7, 23-27 and 33-35 are generic.

6. This application contains claims directed to the following patentably distinct species of the claimed invention: the accessory enzymes listed in claim 17.

With the election of Group I and the election of species of fucosyltransferases, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-7, 23-27 and 33-35 are generic.

7. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Application/Control Number: 09/211,691 Page 5

Art Unit: 1652

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

8. Claims 28-30 and 33-35 are generic to a plurality of disclosed patentably distinct species comprising fusion polypeptides comprising catalytic domains of a glycosyltransferase and an accessory enzyme. If Group II is elected, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed. Claim 31 or 32 will be included with the claims if they are drawn to the same single elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 9. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/211,691 Page 6

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter Tung, Ph.D. whose telephone number is (703) 308-9436. The examiner can normally be reached on Monday-Friday from 9:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy, Ph.D., can be reached on (703) 308-3804. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

PONNATHÀPU ACHUTAMURTHY SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600